In the 50-center international CURE study, diagnosis was delayed in 24.4% of the patients by at least a year. Pavel Kolkhir, MD, study lead and head of the chronic urticaria program in the Institute ...

In managing antihistamine-refractory chronic urticaria, omalizumab and remibrutinib stand out among the most effective treatments across multiple patient-important outcomes, followed by dupilumab, ...

For the sleep disturbances common in chronic spontaneous urticaria (CSU), newer biologic treatments are having an impact. "Patients who come to us with chronic spontaneous urticaria and chronic ...